Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period

Liu, Han‐Qing; Yuan, Bo; An, Yu; Chen, Kai-Jing; Hu, Qi; Hu, Xiaopeng; Zhao, Jiuliang; Yu, Dong; Chen, Yongxin; Li, Weixin; Sun, Chang-Qing; Wang, Jian-Chun; Wang, Cheng; Song, Shuo

doi:10.7150/ijms.50873

Cited by 23 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the clinical hallmarks are well-described, many symptoms are known to carry over into the recovery period, even after the acute phase has subsided. The most common persistent respiratory manifestations documented to date include cough, chest distress, and dyspnea––especially in those with severe/critical disease ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

Miwa

Nakajima

Kaszynski

et al. 2021

Respiratory Investigation

View full text Add to dashboard Cite

Background The long-term repercussions of critical COVID-19 on pulmonary function and imaging studies remains unexplored. In this study, we investigated the pulmonary function and computed tomography (CT) findings of critical COVID-19 patients approximately 100 days after symptom onset. Methods We retrospectively extracted data on critical COVID-19 patients who received invasive mechanical ventilation during hospitalization from April to December 2020 and evaluated their pulmonary function, residual respiratory symptoms, and radiographic abnormalities on CT. Results We extracted 17 patients whose median age was 63 (interquartile range [IQR], 59–67) years. The median lengths of hospitalization and mechanical ventilation were 23 (IQR, 18–38) and 9 (IQR, 6–13) days, respectively. At 100 days after symptom onset, the following pulmonary function abnormalities were noted in 8 (47%) patients: a diffusion capacity of the lung for carbon monoxide (%DL CO ) of <80% for 6 patients (35%); a percent vital capacity (%VC) of <80% for 4 patients (24%); and a percent forced expiratory volume (FEV 1 %) of <70%for 1 patient (6%) who also presented with %DL CO and %VC abnormalities. Twelve (71%) patients reported residual respiratory symptoms and 16 (94%) showed abnormalities on CT. Conclusions Over 90% of the critical COVID-19 patients who underwent invasive mechanical ventilation continued presenting with abnormal imaging studies and 47% of the patients presented with abnormal pulmonary function 100 days after symptom onset. The extent of the residual CT findings might be associated with the degree of abnormal pulmonary function in critical COVID-19 survivors.

show abstract

Section: Introductionmentioning

confidence: 99%

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

Miwa

Nakajima

Kaszynski

et al. 2021

Respiratory Investigation

View full text Add to dashboard Cite

show abstract

“…The basic characteristics of the included articles are summarized in Table 1 . Out of the 34 included articles, 33 were from China [ 12 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ] and 1 from Italy [ 30 ]. All of the included studies were conducted during the first wave of the COVID-19 pandemic.…”

Section: Resultsmentioning

confidence: 99%

Immunoglobulin Response and Prognostic Factors in Repeated SARS-CoV-2 Positive Patients: A Systematic Review and Meta-Analysis

Dembrovszky

Váncsa

Farkas

et al. 2021

Viruses

View full text Add to dashboard Cite

With repeated positivity being an undiscovered and major concern, we aimed to evaluate which prognostic factors may impact repeated SARS-CoV-2 positivity (RSP) and their association with immunoglobulin detectability among recovered patients. A systematic literature search was performed on 5 April 2021. Cohort studies with risk factors for repeated RSP or information about the immunoglobulin response (immunoglobulin M (IgM) and/or immunoglobulin G (IgG)) were included in this analysis. The main examined risk factors were severity of the initial infection, body mass index (BMI), length of hospitalization (LOH), age, and gender, for which we pooled mean differences and odds ratios (ORs). Thirty-four cohort studies (N = 9269) were included in our analysis. We found that increased RSP rate might be associated with IgG positivity; IgG presence was higher in RSP patients (OR: 1.72, CI: 0.87–3.41, p = 0.117). Among the examined risk factors, only mild initial disease course showed a significant association with RSP (OR: 0.3, CI: 0.14–0.67, p = 0.003). Age, male gender, BMI, LOH, and severity of the first episode do not seem to be linked with repeated positivity. However, further prospective follow-up studies focusing on this topic are required.

show abstract

“…Those hospitalized for seven or more days identified disturbed sleep and daytime sleepiness as frequent lingering symptoms [ 6 ]. During recovery from acute COVID-19 infection insomnia symptoms and fatigue were more frequent complaints than depression [ 7 ] or shortness of breath [ 8 ]. There is also concern that insufficient sleep or irregular sleep-wake cycles in patients with severe insomnia disorder and obstructive sleep apnea may impair the immune system and the inflammatory response, increasing vulnerability to viral infections [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Overview of sleep management during COVID-19

Becker

2022

Sleep Medicine

View full text Add to dashboard Cite

The sleep of millions has suffered during the global COVID-19 pandemic. Prevalence rates of 20–45% are reported globally for insomnia symptoms during the pandemic. Affected populations include the public and health care workers. A sleep deprived society faces the increased burden of COVID-related economic disruption, psychosocial problems, substance abuse, and suicide. Disordered sleep is not expected to disappear with control of infection, making interventions acutely necessary. The question becomes how to manage the sleep dysfunction during and after the pandemic. Depression and anxiety are prominent complaints during pandemic restrictions. Insomnia symptoms and fatigue continue even as mood improves in those who are in recovery from COVID-19 infection. Management of disturbed sleep and mental health is particularly needed in frontline health care workers. This overview describes 53 publications, as of February 2021, on disturbed sleep during the pandemic, treatment studies on COVID-related sleep disturbance, and need to rely on current treatment guidelines for common sleep disorders. The available research during the first year of COVID-19 has generally described symptoms of poor sleep rather than addressing treatment strategies. It covers digital cognitive behavioral therapy for insomnia (CBT-i) for the public and frontline workers, recognizing the need of greater acceptance and efficacy of controlled trials of CBT for affected groups. Recommendations based on a tiered public health model are discussed.

show abstract

Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period

Cited by 23 publications

References 20 publications

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms

Immunoglobulin Response and Prognostic Factors in Repeated SARS-CoV-2 Positive Patients: A Systematic Review and Meta-Analysis

Overview of sleep management during COVID-19

Contact Info

Product

Resources

About